From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
Motavizumab (MEDI-524) is an anti-human RSV(respiratorysyncytialvirus) monoclonal antibody. Motavizumab can be used in respiratorysyncytialvirus infection in high-risk infants research .
BMS-433771 is a potent orally active inhibitor of respiratorysyncytialvirus (RSV). BMS-433771 is active against both A and B groups of RSV, with an average EC50 of 20 nM. BMS-433771 can be used for the research of respiratory tract disease .
BMS-433771 dihydrochloride hydrate is a potent orally active inhibitor of respiratorysyncytialvirus (RSV). BMS-433771 dihydrochloride hydrate is active against both A and B groups of RSV, with an average EC50 of 20 nM. BMS-433771 dihydrochloride hydrate can be used for the research of respiratory tract disease .
RFI-641 is a selective inhibitor of the respiratorysyncytialvirus (RSV), with an IC50 of 50 nM. RFI-641 inhibit binding and fusion of enveloped virus via interaction with the viral fusion protein .
RSV-IN-4 (Compound 2) is a dual inhibitor of respiratorysyncytialvirus (RSV) and influenza virus A (IAV). RSV-IN-4 shows anti-RSV activity (EC50 = 11.76 μM) .
RSV-IN-3 (Compound 1) is a dual inhibitor of respiratorysyncytialvirus (RSV) and influenza virus A (IAV). RSV-IN-3 shows anti-RSV activity (EC50 = 32.70 μM) .
4,5-O-Dicaffeoyl quinic acid methyl ester (compound 4), a dicaffeoylquinic acid, has potent antiviral activity against respiratorysyncytialvirus (RSV) with an IC50 of 0.63 μg/mL and a CC50 of 118.68 μg/mL.
IDB-002 is a human monoclonal antibody (mAb) targeting F/Fusion glycoprotein F0. IDB-002 can be used in respiratorysyncytialvirus infection research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
Sophoranol is an alkaloid that can be isolated from S. flavescens, with antiviral activity. Sophoranol has anti-HBV (hepatitis B virus) activity. Sophoranol shows potent antiviral activities against respiratorysyncytialvirus (RSV) with an IC50 of 10.4 μg/mL .
RSV604 (A-60444) is an inhibitor of respiratorysyncytialvirus (RSV) replication. RSV604 targets the nucleocapsid protein, with a Kd of 1.6 μM. RSV604 displays submicromolar activity against numerous clinical isolates of both the A and B subtypes of RSV (average EC50s=0.8 μM) .
GHP-88309 is a broad-spectrum, orally active antiviral agent targeting paramyxoviruses, that targets the viral polymerase, interupts the viral RNA synthesis, and inhibits respiratorysyncytialvirus (RSV), measles virus (MeV), and canine distemper virus (CDV) with EC50 of 0.06-1.2 μM. GHP-88309 exhibits anti-infectious efficacy in mouse models .
JNJ 2408068 is a potent RSV (respiratorysyncytialvirus) inhibitor. JNJ 2408068 significantly inhibits replication of RSV A and B subtypes in the lungs of cotton rats without any evidence of toxicity. The minimum protective dose of JNJ 2408068 appears to be approximately 0.39 mg/kg .
4-Methoxycinnamaldehyde (p-Methoxycinnamaldehyde), an active constituent of Agastache rugosa, exhibits cytoprotective activity against respiratorysyncytialvirus (RSV) in human larynx carcinoma cell line. 4-Methoxycinnamaldehyde effectively inhibits cytopathic effect of RSV with an estimated IC50 of 0.055 μg/mL .
Ac-CoA Synthase Inhibitor1 is a potent, reversible acetate-dependent acetyl-CoA synthetase 2 (ACSS2) inhibitor with an IC50 of 0.6 μM . Ac-CoA Synthase Inhibitor1 inhibits the respiratorysyncytialvirus (RSV) .
RSV-IN-5 (Compound 4) is a potent dual inhibitor of wild-type and mutant respiratorysyncytialvirus (RSV) fusion proteins. RSV-IN-5 exhibits potent anti-RSV activities against not only wild-type A2 F protein (EC50=2.0 nM), but also D486N-mutant F protein (EC50=8.1 nM) .
4-Methoxycinnamaldehyde (Standard) is the analytical standard of 4-Methoxycinnamaldehyde. This product is intended for research and analytical applications. 4-Methoxycinnamaldehyde (p-Methoxycinnamaldehyde), an active constituent of Agastache rugosa, exhibits cytoprotective activity against respiratorysyncytialvirus (RSV) in human larynx carcinoma cell line. 4-Methoxycinnamaldehyde effectively inhibits cytopathic effect of RSV with an estimated IC50 of 0.055 μg/mL[1].
Palivizumab (MEDI 493) is a humanized monoclonal antibody against respiratorysyncytialvirus (RSV). Palivizumab can bind to RSV F protein with a Kd value of 1.4 nM. Palivizumab can prevent respiratorysyncytialvirus infection in cotton mice .
AVG-233 is a potent, orally active RNA dependent RNA polymerase (RdRp) inhibitor. AVG-233 prevents initiation of the viral polymerase complex at the promoter. AVG-233 binding site is present in the L1-1749 fragment. AVG-233 has nanomolar activity against both RSV strains and clinical RSV isolates (EC50=0.14-0.31 μM). AVG-233 can be used for research of respiratorysyncytialvirus (RSV) .
RSV/IAV-IN-3 (compound 14'i) is a dual inhibitor of respiratorysyncytialvirus (RSV) and influenza A virus (IAV) with EC50 values of 2.92 µM and 1.90 µM,respectively. RSV/IAV-IN-3 has antiviral effect against H1N1 and H3N2 with EC50 values of 3.25 µM and 1.50 µM in MDCK cells, respectively. RSV/IAV-IN-3 significantly inhibits the activity of luciferase in a dose-dependent manner, with an EC50 of 3.89 µM. RSV/IAV-IN-3 inhibits IAV infectivity and RdRp activity. RSV/IAV-IN-3 inhibits IAV and RSV replication at the post-entry stage .
SyncytialVirus Inhibitor-1 is a potent, orally bioavailable respiratorysyncytialvirus (RSV) fusion inhibitor with EC50s of 0.002 μM, 0.004 μM, and 0.002 μM for RSV Long, RSV A2, and RSV B strains, respectively .
RSV604 R enantiomer is the R-enantiomer of RSV604. RSV604 is an inhibitor of respiratorysyncytialvirus (RSV) replication. R-enantiomer is less active against RSV.
Retavibart is a human respiratorysyncytialvirus (RSV) fusion glycoprotein F. Retavibart can be used for antiviral research. Isotype control: Human IgG1 kappa .
Nirsevimab (MEDI8897) is a recombinant monoclonal antibody against human respiratorysyncytialvirus (RSV). Nirsevimab has neutralizing activity against RSV A and RSV B viruses, with IC50 values of 5.42 ng/mL and 9.71 ng/mL, respectively. Nirsevimab can be used for research on respiratory infections .
YM 53403 is an anti-respiratorysyncytialvirus (RSV) agent, with an EC50 of 0.20 μM. YM 53403 potently inhibits the replication of RSV strains belonging to both A and B subgroups .
IN-002 is a human monoclonal antibody (mAb) targeting F, Fusion glycoprotein F0. IN-002 can be used in respiratorysyncytialvirus (RSV) infections research.
Sisunatovir (RV521) hydrochloride is a potent and orally active respiratorysyncytialvirus (RSV) inhibitor with IC50 values of 1.4, 1.0 nM for RSV A, RSV B, respectively. Sisunatovir hydrochloride inhibits RSV infection and reduces virus titers in the lungs of mice .
Sisunatovir (RV521) is a potent and orally active respiratorysyncytialvirus (RSV) inhibitor with IC50 values of 1.4, 1.0 nM for RSV A, RSV B, respectively. Sisunatovir inhibits RSV infection and reduces virus titers in the lungs of mice .
ALS-8112 is a potent and selective respiratorysyncytialvirus (RSV) polymerase inhibitor. The 5'-triphosphate form of ALS-8112 inhibits RSV polymerase with an IC50 of 0.02 μM.
EVO-46120 is a human monoclonal antibody (mAb) targeting F, Fusion glycoprotein F0. EVO-46120 can be used in respiratorysyncytialvirus (RSV) and metapneumovirus infections research.
EVO-46135 is a human monoclonal antibody (mAb) targeting F/Fusion glycoprotein F0. EVO-46135 can be used in Respiratorysyncytialvirus infections and Metapneumovirus infections research.
Antiviral agent 58 (Compound J1) is an orally active antiviral agent with broad-spectrum antiviral activity against enveloped viruses, including influenza A virus (IAV), respiratorysyncytialvirus (RSV), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), human coronavirus OC43 (HCoV-OC43), herpes simplex virus type 1 (HSV-1), and HSV-2 .
AZ-27 is a respiratorysyncytialvirus (RSV) inhibitor. AZ-27 can differentially suppress various RSV polymerase activities at the promoter, thereby inhibiting the early stages of mRNA transcription and genome replication by targeting the promoter .
PC786 is an inhaled respiratorysyncytialvirus (RSV) L protein polymerase inhibitor. PC786 demonstrates potent antiviral activity against RSV-A (IC50 <0.09 to 0.71 nM) and RSV-B (IC50, 1.3 to 50.6 nM) .
RSV L-protein-6 (Compound 19a) is a respiratorysyncytialvirus polymerase inhibitor, with an IC50 of 13 nM in SPA primer extensions enzymatic assay. RSV L-protein-6 can inhibit RSV replication in Hela cells .
AM679 is a potent, selective 5-lipoxygenase-activating protein (FLAP) inhibitor with an IC50 of 2 nM in a human FLAP membrane binding assay. AM679 markedly reduces the respiratorysyncytialvirus-driven ocular pathology as well as the synthesis of cysteinyl leukotrienes (CysLTs) in the eye .
Fusion glycoprotein 92-106 is a polypeptide from fusion protein of respiratorysyncytialvirus (RSV). Fusion glycoprotein 92-106 acts as MHC class I-restricted CTL epitope, that all 15 amino acids are required for efficient recognition by cytotoxic T lymphocyte (CTL) .
AR-201 is a human IgG1 monoclonal antibody (mAb) targeting F, Fusion glycoprotein F0. AR-201 has anti-respiratorysyncytialvirus (RSV) activity. AR-201 can be used in lower respiratory tract illness (LRTI) research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
Ziresovir (AK0529;RO-0529) is a potent, selective, and orally bioavailable respiratorysyncytialvirus (RSV) fusion (F) protein (RSV F) protein inhibitor. Ziresovir shows anti-RSV activity (EC50=3 nM) and highlights pharmacokinetics in animal species .
RSM-01 is a human IgG1 monoclonal antibody (mAb) targeting F, Fusion glycoprotein F0. RSM-01 has anti-respiratorysyncytialvirus (RSV) activity. VIR-7229 can be used in lower respiratory tract illness (LRTI) research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
3,4-Di-O-caffeoyl quinic acid methyl ester (Macroantoin F) is a dicaffeoyl derivative isolated from the rhizome of Elephantopus scaber Linn. 3,4-Di-O-caffeoyl quinic acid methyl ester exhibited in vitro antiviral activity against respiratorysyncytialvirus (< a href=" " class="link-product" target="_blank">RSV) with an IC50 value of 0.78 μg/mL .
VIR-8190 is a human IgG1 monoclonal antibody (mAb) targeting F, Fusion glycoprotein F0. VIR-8190 can be used in respiratorysyncytialvirus (RSV) and metapneumovirus infections research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
Clesrovimab (MK1654) is a humanized IgG1 monoclonal antibody against the protein F of respiratorysyncytialvirus (RSV) with an extended half-life. Clesrovimab can bind to the conserved site IV of the RSV F glycoprotein and neutralize various strains containing RSV F. Clesrovimab can be used in the research of RSV diseases .
Rostafuroxin (PST 2238), a digitoxigenin derivative, is an orally active and potent Na +,K +-ATPase (ATP1A1) antognist. Rostafuroxin binds specifically to the ATP1A1 extracellular domain and blocks respiratorysyncytialvirus (RSV)-triggered EGFR Tyr845 phosphorylation. Rostafuroxin has antihypertensive and anti-RSV activity .
Inarigivir soproxil (SB9200) is an agonist of innate immunity and shows potent antiviral activity against resistant HCV variants, with EC50s of 2.2 and 1.0 μM for HCV 1a/1b in cells of genotype 1 HCV replicon systems. Inarigivir soproxil, an orally bioavailable proagent of SB 9000, has broad-spectrum antiviral activity against RNA viruses including HCV, norovirus, respiratorysyncytialvirus and influenza and HBV .
Cyclopiazonic acid is an endoplasmic reticulum calcium ATPase (ECAs) inhibitor and human respiratorysyncytialvirus (RSV) inhibitor (EC50 value of 4.13 μ M), which can reduce the antagonistic effect of 5-HT receptors in rat thoracic aorta, induce p53 dependent cell apoptosis and reproductive toxicity in mouse testes, and inhibit the biological activation of aflatoxin B [1][4][5].
Verdinexor (KPT-335) is an orally active inhibitor for selective inhibitor of nuclear export (SINE). Verdinexor inhibits the respiratorysyncytialvirus A2 (RSV A2) replication with an IC50 of 0.96 µM. Verdinexor inhibits the function of nuclear export protein Exportin 1 (XPO1/CRM1), inhibiting pro-inflammatory responses. Verdinexor exhibits antitumor effciency .
Mindeudesivir (JT001; VV116; GS-621763-d1) hydrobromide is a deuterated version of Remdesivir (HY-104077), a highly orally active nucleoside antiviral against SARS-CoV-2 and respiratorysyncytialvirus (RSV). Mindeudesivir hydrobromide retains the antiviral activity of Remdesivir against COVID-19, and is the first domestically produced deuterium targeting the COVID-19 .
Rostafuroxin (Standard) is the analytical standard of Rostafuroxin. This product is intended for research and analytical applications. Rostafuroxin (PST 2238), a digitoxigenin derivative, is an orally active and potent Na+,K+-ATPase (ATP1A1) antognist. Rostafuroxin binds specifically to the ATP1A1 extracellular domain and blocks respiratorysyncytialvirus (RSV)-triggered EGFR Tyr845 phosphorylation. Rostafuroxin has antihypertensive and anti-RSV activity .
JNJ-8003 is a potent inhibitor of RSV Polymerase. JNJ-8003 inhibits nucleotide polymerization of RNA transcription and replication at the early stages .
2'-Deoxy-2'-fluorouridine is a derivative of the pyrimidine nucleoside uridine. 2'-Deoxy-2'-fluorouridine is a nucleoside analog that inhibits the replication of wild-type viruses by binding to the viral RNA. Hepatitis C polyU/UC RNA strands containing 2'-Deoxy-2'-fluorouridine, bind to RIG-I but do not activate RIG-I signaling in a reporter assay using Huh7 cells. 2'-Deoxy-2'-fluorouridine also has been used as a starting material in the synthesis of respiratorysyncytialvirus (RSV) polymerase inhibitors. 2'-Deoxy-2'-fluorouridine can incorporate into DNA and RNA in rat and woodchuck model upon administration. 2'-Deoxy-2'-fluorouridine can be studied in anti-viral research .
HRSV/HMPV-IN-1 (compound 3) is a HRSV/HMPV inhibitor with the EC50 values of ＜ 0.2 μM and ＜ 0.5 μM for human RSV-A and human MPV A2 TN/94-49, respectively. HRSV/HMPV-IN-1 can be used for study of bronchiolitis and pneumonia .
2'-Deoxy-2'-fluorouridine-d2 is the deuterium labeled 2'-Deoxy-2'-fluorouridine . 2'-Deoxy-2'-fluorouridine is a derivative of the pyrimidine nucleoside uridine. 2'-Deoxy-2'-fluorouridine is a nucleoside analog that inhibits the replication of wild-type viruses by binding to the viral RNA. Hepatitis C polyU/UC RNA strands containing 2'-Deoxy-2'-fluorouridine, bind to RIG-I but do not activate RIG-I signaling in a reporter assay using Huh7 cells. 2'-Deoxy-2'-fluorouridine also has been used as a starting material in the synthesis of respiratorysyncytialvirus (RSV) polymerase inhibitors. 2'-Deoxy-2'-fluorouridine can incorporate into DNA and RNA in rat and woodchuck model upon administration. 2'-Deoxy-2'-fluorouridine can be studied in anti-viral research .
FLS-359 is a selective, orally active allosteric modulator for sirtuin 2, with the IC50 of 3 μM. FLS-359 exhibits antiviral activity against RNA and DNA virus, through inhibition of DNA/RNA replication .
Fusion glycoprotein 92-106 is a polypeptide from fusion protein of respiratorysyncytialvirus (RSV). Fusion glycoprotein 92-106 acts as MHC class I-restricted CTL epitope, that all 15 amino acids are required for efficient recognition by cytotoxic T lymphocyte (CTL) .
Motavizumab (MEDI-524) is an anti-human RSV(respiratorysyncytialvirus) monoclonal antibody. Motavizumab can be used in respiratorysyncytialvirus infection in high-risk infants research .
Palivizumab (MEDI 493) is a humanized monoclonal antibody against respiratorysyncytialvirus (RSV). Palivizumab can bind to RSV F protein with a Kd value of 1.4 nM. Palivizumab can prevent respiratorysyncytialvirus infection in cotton mice .
Nirsevimab (MEDI8897) is a recombinant monoclonal antibody against human respiratorysyncytialvirus (RSV). Nirsevimab has neutralizing activity against RSV A and RSV B viruses, with IC50 values of 5.42 ng/mL and 9.71 ng/mL, respectively. Nirsevimab can be used for research on respiratory infections .
IDB-002 is a human monoclonal antibody (mAb) targeting F/Fusion glycoprotein F0. IDB-002 can be used in respiratorysyncytialvirus infection research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
Retavibart is a human respiratorysyncytialvirus (RSV) fusion glycoprotein F. Retavibart can be used for antiviral research. Isotype control: Human IgG1 kappa .
IN-002 is a human monoclonal antibody (mAb) targeting F, Fusion glycoprotein F0. IN-002 can be used in respiratorysyncytialvirus (RSV) infections research.
EVO-46120 is a human monoclonal antibody (mAb) targeting F, Fusion glycoprotein F0. EVO-46120 can be used in respiratorysyncytialvirus (RSV) and metapneumovirus infections research.
EVO-46135 is a human monoclonal antibody (mAb) targeting F/Fusion glycoprotein F0. EVO-46135 can be used in Respiratorysyncytialvirus infections and Metapneumovirus infections research.
AR-201 is a human IgG1 monoclonal antibody (mAb) targeting F, Fusion glycoprotein F0. AR-201 has anti-respiratorysyncytialvirus (RSV) activity. AR-201 can be used in lower respiratory tract illness (LRTI) research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
RSM-01 is a human IgG1 monoclonal antibody (mAb) targeting F, Fusion glycoprotein F0. RSM-01 has anti-respiratorysyncytialvirus (RSV) activity. VIR-7229 can be used in lower respiratory tract illness (LRTI) research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
VIR-8190 is a human IgG1 monoclonal antibody (mAb) targeting F, Fusion glycoprotein F0. VIR-8190 can be used in respiratorysyncytialvirus (RSV) and metapneumovirus infections research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
Clesrovimab (MK1654) is a humanized IgG1 monoclonal antibody against the protein F of respiratorysyncytialvirus (RSV) with an extended half-life. Clesrovimab can bind to the conserved site IV of the RSV F glycoprotein and neutralize various strains containing RSV F. Clesrovimab can be used in the research of RSV diseases .
4-Methoxycinnamaldehyde (p-Methoxycinnamaldehyde), an active constituent of Agastache rugosa, exhibits cytoprotective activity against respiratorysyncytialvirus (RSV) in human larynx carcinoma cell line. 4-Methoxycinnamaldehyde effectively inhibits cytopathic effect of RSV with an estimated IC50 of 0.055 μg/mL .
Cyclopiazonic acid is an endoplasmic reticulum calcium ATPase (ECAs) inhibitor and human respiratorysyncytialvirus (RSV) inhibitor (EC50 value of 4.13 μ M), which can reduce the antagonistic effect of 5-HT receptors in rat thoracic aorta, induce p53 dependent cell apoptosis and reproductive toxicity in mouse testes, and inhibit the biological activation of aflatoxin B [1][4][5].
4,5-O-Dicaffeoyl quinic acid methyl ester (compound 4), a dicaffeoylquinic acid, has potent antiviral activity against respiratorysyncytialvirus (RSV) with an IC50 of 0.63 μg/mL and a CC50 of 118.68 μg/mL.
Sophoranol is an alkaloid that can be isolated from S. flavescens, with antiviral activity. Sophoranol has anti-HBV (hepatitis B virus) activity. Sophoranol shows potent antiviral activities against respiratorysyncytialvirus (RSV) with an IC50 of 10.4 μg/mL .
4-Methoxycinnamaldehyde (Standard) is the analytical standard of 4-Methoxycinnamaldehyde. This product is intended for research and analytical applications. 4-Methoxycinnamaldehyde (p-Methoxycinnamaldehyde), an active constituent of Agastache rugosa, exhibits cytoprotective activity against respiratorysyncytialvirus (RSV) in human larynx carcinoma cell line. 4-Methoxycinnamaldehyde effectively inhibits cytopathic effect of RSV with an estimated IC50 of 0.055 μg/mL[1].
3,4-Di-O-caffeoyl quinic acid methyl ester (Macroantoin F) is a dicaffeoyl derivative isolated from the rhizome of Elephantopus scaber Linn. 3,4-Di-O-caffeoyl quinic acid methyl ester exhibited in vitro antiviral activity against respiratorysyncytialvirus (< a href=" " class="link-product" target="_blank">RSV) with an IC50 value of 0.78 μg/mL .
RSV G protein is a type II, highly glycosylated membrane protein with a full length of 292-319 amino acids (AA), an intracellular cytoplasmic tail (AA 1-37), and a transmembrane domain (AA 38 -66) and the extracellular domain ending in its carboxyl terminus.The RSV G protein has broad effects on the biology of RSV infection as well as host immune responses and infection-associated diseases.glycoprotein/G Protein, HRSV (HEK293, His) is the recombinant Virus-derived glycoprotein/G protein, expressed by HEK293 , with C-His labeled tag.
The fusion glycoprotein F0/F protein is initially an inactive precursor that is cleaved by furin-like proteases to produce the mature F1 and F2 fusion glycoproteins.As a class I viral fusion protein, it undergoes prefusion, prehairpin, and postfusion states.Fusion glycoprotein F0/F Protein, HRSV (sf9, His) is the recombinant Virus-derived Fusion glycoprotein F0/F protein, expressed by Sf9 insect cells , with C-His labeled tag.
A glycoprotein/G protein critical in the immune response forms the interleukin-31 receptor with OSMR.This receptor activates STAT3 and, to a lesser extent, STAT1 and STAT5, playing a critical role in skin immunity and mediating IL31-induced itch, possibly involving TRPA1 and TRPV1.Glycoprotein/G Protein, HRSV (95% Homology, HEK293, His) is the recombinant Virus-derived Glycoprotein/G protein, expressed by HEK293 , with C-His labeled tag.
The fusion glycoprotein F0/F protein is initially an inactive precursor that is cleaved by furin-like proteases to produce the mature F1 and F2 fusion glycoproteins. As a class I viral fusion protein, it undergoes prefusion, prehairpin, and postfusion states. Fusion glycoprotein F0/F Protein, HRSV (His, B2M) is the recombinant Virus-derived Fusion glycoprotein F0/F protein, expressed by E. coli , with N-B2M, N-6*His labeled tag.
A glycoprotein/G protein critical in the immune response forms the interleukin-31 receptor with OSMR.This receptor activates STAT3 and, to a lesser extent, STAT1 and STAT5, playing a critical role in skin immunity and mediating IL31-induced itch, possibly involving TRPA1 and TRPV1.glycoprotein/G Protein, HRSV (sf9, His) is the recombinant Virus-derived glycoprotein/G protein, expressed by Sf9 insect cells , with C-His labeled tag.
F0/F is a class of viral fusion proteins that, as an inactive precursor, are cleaved by a furfurin-like protease at two sites to produce mature F1 and F2 fusion glycoproteins.The F protein can mediate cell-cell fusion, lead to syncytial formation, and trigger p53-dependent apoptosis in the later stages of infection.Fusion glycoprotein F0/F Protein, HRSV (AFX60213, sf9, His) is the recombinant Virus-derived Fusion glycoprotein F0/F protein, expressed by Sf9 insect cells , with C-His labeled tag.
F0/F is a class of viral fusion proteins that, as an inactive precursor, are cleaved by a furfurin-like protease at two sites to produce mature F1 and F2 fusion glycoproteins.The F protein can mediate cell-cell fusion, lead to syncytial formation, and trigger p53-dependent apoptosis in the later stages of infection.Fusion glycoprotein F0/F Protein, HRSV (AHX57537, sf9, His) is the recombinant Virus-derived Fusion glycoprotein F0/F protein, expressed by Sf9 insect cells , with C-His labeled tag.
A glycoprotein/G protein critical in the immune response forms the interleukin-31 receptor with OSMR.This receptor activates STAT3 and, to a lesser extent, STAT1 and STAT5, playing a critical role in skin immunity and mediating IL31-induced itch, possibly involving TRPA1 and TRPV1.glycoprotein/G Protein, HRSV (93% Homology, HEK293, His) is the recombinant Virus-derived glycoprotein/G protein, expressed by HEK293 , with C-His labeled tag.
The fusion glycoprotein F0/F protein is cleaved to generate mature F1 and F2 fusion glycoproteins.It functions as a viral fusion protein, promoting the fusion of virus and cell membranes through different state transitions.Fusion glycoprotein F0/F Protein, HRSV (P11209, sf9, His) is the recombinant Virus-derived Fusion glycoprotein F0/F protein, expressed by Sf9 insect cells , with C-His labeled tag.
Mindeudesivir (JT001; VV116; GS-621763-d1) hydrobromide is a deuterated version of Remdesivir (HY-104077), a highly orally active nucleoside antiviral against SARS-CoV-2 and respiratorysyncytialvirus (RSV). Mindeudesivir hydrobromide retains the antiviral activity of Remdesivir against COVID-19, and is the first domestically produced deuterium targeting the COVID-19 .
2'-Deoxy-2'-fluorouridine-d2 is the deuterium labeled 2'-Deoxy-2'-fluorouridine . 2'-Deoxy-2'-fluorouridine is a derivative of the pyrimidine nucleoside uridine. 2'-Deoxy-2'-fluorouridine is a nucleoside analog that inhibits the replication of wild-type viruses by binding to the viral RNA. Hepatitis C polyU/UC RNA strands containing 2'-Deoxy-2'-fluorouridine, bind to RIG-I but do not activate RIG-I signaling in a reporter assay using Huh7 cells. 2'-Deoxy-2'-fluorouridine also has been used as a starting material in the synthesis of respiratorysyncytialvirus (RSV) polymerase inhibitors. 2'-Deoxy-2'-fluorouridine can incorporate into DNA and RNA in rat and woodchuck model upon administration. 2'-Deoxy-2'-fluorouridine can be studied in anti-viral research .
